Revenue segments as reported by the company.

Immunology

Hematologic Oncology

Aesthetics

Neuroscience

Eye Care

Women's Health

Other Key Products

All other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Acquired in-process research and development

Other operating expense

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

AbbVie

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

AbbVie surpasses Q4 earnings forecast, eyes growth amid challenges

AbbVie's strong performance in Q4 2022 exceeded expectations, driven by key products like SKYRIZI and RINVOQ. Despite challenges in revenue and HUMIRA erosion, the company is focused on innovation and growth opportunities. Strategic investments in R&D and BD aim to navigate market dynamics and drive future success.

AbbVie surpasses Q1 expectations, eyes international growth amid challenges

AbbVie's Q1 2023 performance exceeded expectations, driven by key product sales and strong international results. While facing challenges in the U.S. market and inflationary pressures, the company remains confident in its long-term growth prospects and strategic initiatives.

AbbVie surpasses Q2 expectations, eyes revenue growth opportunities

AbbVie's Q2 2023 earnings call highlighted strong financial performance, successful execution in key therapeutic areas, and a promising outlook for revenue growth. Despite challenges like biosimilar competition and market dynamics, the company remains confident in its ability to deliver value and maintain growth.

AbbVie exceeds Q3 expectations, focuses on pipeline growth strategies

AbbVie's strong Q3 performance driven by key products and growth platforms, with positive trial results.
Challenges in aesthetics sales and Medicare drug pricing program offset by long-term growth opportunities.
Confidence in pipeline assets and strategic focus on combination therapies for future growth.
Maintaining strong market positions and investing in transformative therapies for competitive advantage.

AbbVie exceeds Q4 expectations, eyes growth through strategic acquisitions

AbbVie's stellar performance in Q4 2023 showcased strong sales growth, successful pipeline advancements, and strategic acquisitions. While facing challenges such as pricing pressures and safety concerns, the company is well-positioned to capitalize on opportunities in expanding its portfolio and driving growth through innovation and strategic partnerships.

AbbVie exceeds Q1 expectations, raises full-year guidance on strong sales growth

AbbVie's Q1 performance exceeded expectations, with strong sales growth in key products. The company raised full-year guidance and remains confident in maintaining good access for its brands. Challenges in aesthetics sales and inventory management are being addressed for future growth.

AbbVie reports robust Q2 results and raises 2024 guidance

AbbVie's strong Q2 performance, raised guidance, and strategic acquisitions highlight its growth trajectory.
Despite near-term challenges, the company's focus on key growth areas positions it for long-term success.
Investments in innovation and market expansion underscore AbbVie's commitment to sustained growth.
Overall, AbbVie's performance in Q2 2024 reflects a resilient and forward-looking approach to business.

AbbVie reports strong Q3 performance, raises guidance and dividend

AbbVie's Q3 2024 performance showcased robust sales growth, increased dividend, and raised revenue guidance, reflecting financial strength and market leadership.
The company's focus on long-term sustainability through investments, acquisitions, and pipeline advancements highlights a commitment to innovation and growth.
While facing challenges in clinical trial management and market competition, AbbVie remains well-positioned to leverage opportunities in diverse therapeutic areas for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

The U.S. Food and Drug Administration has approved AbbVie Inc's ABBV, +2.25% Rinvoq, a JAK kinase inhibitor, to treat moderate-to-severe rheumatoid arthritis in adults for whom methotrexate hasn't worked, AbbVie announced Friday.

FDA approves AbbVie's Rinvoq to treat moderate-to-severe RA

The U.S. Food and Drug Administration on Friday approved AbbVie's new treatment for rheumatoid arthritis, a win for the drugmaker seeking to widen its portfolio.

FDA approves Humira maker AbbVie's new rheumatoid arthritis drug

Bristol-Myers

Guardant Health Inc

Illumina

Intuitive Surgical

Each of these healthcare companies takes a different approach to fighting cancer, but all have what it takes to be long-term winners in your portfolio.

5 Top Cancer-Fighting Stocks to Buy Now

Bank of America

Cisco Systems

Intel

Johnson & Johnson

JPMorgan Chase & Co

Microsoft

Exxon Mobil

These stocks are projected to offer the biggest dividend hikes in 2020, which should bolster their prices in a volatile market, according to Goldman Sachs.

8 Blue Chips Seen Fueled By Major Dividend Growth As Outlook Darkens

Let's see if AbbVie Inc. (ABBV) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks.

Should Value Investors Consider AbbVie (ABBV) Stock Now?

Novartis

Pfizer

And the one big pharma most likely to benefit the most.

5 Biggest New Drugs Approved in 2019 So Far

Gilead Sciences

After the several years of HCV sales fall, the first half of 2019 showed us the early signs of stabilization.

The Future Of HCV Market Duopoly

CVS Health

3 Embarrassingly Cheap Dividend Stocks.

Philip Morris

When looking for the best dividend stocks, you need to look beyond the yield.

3 Top Stocks With High Dividend Yields: ABBV, BP & PM

Archer-Daniels-Midland Company

FedEx

Kraft Heinz

ArcelorMittal

Occidental Petroleum

Ryanair Hlds

Don’t wait for a turnaround, there are better choices in this market.

7 Large-Cap Stocks to Sell Right Now

Allergan

ABBV is a large biopharmaceutical corporation whose success is primarily driven by the blockbuster drug Humira, which makes up about 60% of the company's revenue.

AbbVie Will Be Formidable After Acquiring Allergan

Chevron

Phillips 66

Top Research Reports: Chevron, AbbVie, Phillips 66 & More

Merck

These five-star medicines should continue to push the industry higher in the next decade, despite the political blowback surrounding U.S. prescription drug prices.

These 5 Prescription Drugs Will Generate a Jaw-Dropping $62.3 Billion in 2024

EVP, Chief Strategy Officer of Abbvie Inc (30-Year Financial, Insider Trades) Henry O Gosebruch (insider trades) bought 30,000 shares of ABBV on 07/29/2019 at an average price of $67.28 a share.

Abbvie Inc (ABBV) EVP, Chief Strategy Officer Henry O Gosebruch Bought $2 million of Shares

The beleaguered big pharma company delivered a better-than-expected report.

5 Things You Need to Know From AbbVie's Q2 Earnings Results

AbbVie Inc. (ABBV) CEO Rick Gonzalez on Q2 2019 Results - Earnings Call Transcript

AbbVie earnings for the second quarter of 2019 have ABBV stock up on Friday thanks to it beating EPS and revenue estimates.
The post AbbVie Earnings: ABBV Stock Pops on Q2 Beat appeared first on InvestorPlace.

AbbVie Earnings: ABBV Stock Pops on Q2 Beat

AbbVie (ABBV) beats second-quarter estimates for both earnings and revenues. Biosimilar competition impacts Humira sales in ex-U.S.

AbbVie (ABBV) Beats on Q2 Earnings & Sales, Raises EPS View

Shares of AbbVie Inc. ABBV, -1.19% rose 2% in premarket trade Friday after the drugmaker reported profit and revenue that topped Wall Street expectations.

AbbVie stock up 2% after earnings beat

AbbVie's (ABBV) second-quarter 2019 earnings and revenues both beat estimates. The company raised its guidance for adjusted earnings in 2019.

AbbVie (ABBV) Beats Q2 Earnings and Revenues, Shares Up

AbbVie (NYSE: ABBV) reported second-quarter earnings of $2.26 per share, which beat the analyst consensus estimate of $2.20.

AbbVie Reports Q2 Earnings Beat, Raises Guidance

AbbVie earnings modestly topped Q2 views while the drug giant's flat sales also exceeded expectations. AbbVie stock rose before Friday's open.

AbbVie Earnings Top Views, Guidance Raised

AMC Entertainment

AMTD International Inc

Home Depot

Altria

AT&T

Unilever

Welltower

No matter what your investing style, there’s always a place for passive income. Here are nine dividend stocks to buy, ranging from conservative, balanced, and speculative ideas.

9 Dividend Stocks to Buy to Suit Any Investing Style

Bayer AG

Roche Holding AG

Sanofi

Large-Cap Pharmaceuticals Industry Near-Term Outlook Bright

AbbVie Inc. (NYSE:ABBV) is one of the largest pharmaceutical companies in the U.S.

News for AbbVie Stock (ABBV)